Long-Term Safety of Pirtobrutinib in Participants From Study LOXO-BTK-18001 With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Eli Lilly and Company
Summary
Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Are currently enrolled and active in the originator study, LOXO-BTK-18001. A participant is considered active in the study if they are: * receiving study intervention * in the short-term follow-up period, or * in the long-term follow-up period Exclusion Criteria: * Were a participant in the Phase 1b cohort of Study LOXO-BTK-18001
Interventions
- DrugPirtobrutinib
Administered orally.
Locations (36)
- Sylvester Comprehensive Cancer CenterMiami, Florida
- Florida Cancer SpecialistsSarasota, Florida
- The Emory ClinicAtlanta, Georgia
- Northwestern UniversityChicago, Illinois
- Dana-Farber Cancer InstituteBoston, Massachusetts
- Mayo Clinic- MinnesotaRochester, Minnesota